Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
Completed · Phase 3
Conditions studied: Prostate Cancer
In brief
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, participants were randomly selected (like flipping a coin) to receive either degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide. The treatment was given for three months and the prostate size was measured by ultra sound at the beginning and at the end of the trial. The participants were required to come to the clinic for 5 or 6 visits during the three months.
Key facts
- Study ID
- NCT00833248
- Run by
- Ferring Pharmaceuticals
- People needed
- 246
- Starts
- 2009-04-01
- Expected to finish
- 2011-09-01
- Last updated by the study team
- 2012-10-04
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- Patient has given written informed consent before any trial-related activity is performed.
- Has a confirmed prostate cancer in which this type of treatment is needed.
You may not qualify if…
- Previous treatment for prostate cancer
- Previous trans-urethral resection of the prostate
- Patients who are lymph node positive or have other metastatic disease
- Use of urethral catheter
- Current treatment with a 5-alpha reductase inhibitor or α-adrenoceptor antagonist.
- History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
- Hypersensitivity towards any component of the investigational product
- Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.
- Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)
- Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.
Where it is running
- Urology Centers of Alabama — Homewood, Alabama, United States
- Alaska Urological Association — Anchorage, Alaska, United States
- Arizona Urologic Specialists — Tuscon, Arizona, United States
- Orange County Urology — Lagua Hills, California, United States
- Tri-Valley Urology Medical Group — Murrieta, California, United States
- Connecticut Clinical Research Center — Middlebury, Connecticut, United States
- South Florida Medical Research — Aventura, Florida, United States
- DCT -Celebration, LLC dba Discovery Clinical Trials — Celebration, Florida, United States
- Pinellas Urology Inc. — St. Petersburg, Florida, United States
- Palm Beach Urology Associates — Wellington, Florida, United States
- Summit Research Institute — Bloomington, Indiana, United States
- Northeast Indiana Research — Fort Wayne, Indiana, United States
- Urology Center Research Institute — Englewood, New Jersey, United States
- Urology Group of New Mexico — Albuquerque, New Mexico, United States
- Premier Medical Group of Hudson — Baldwinsville, New York, United States
- University Urology Associates — New York, New York, United States
- Urology Associates — Nashville, Tennessee, United States
- Urology of Virginia — Norfolk, Virginia, United States
- Hopital Jean Minjoz — Besançon, France
- Institut Bergonié — Bordeaux, France
- Centre Francois Baclesse — Caen, France
- CHU Henri Mondor — Créteil, France
- Centre Oscar Lambret — Lille, France
- Centre Leon Berard — Lyon, France
- Alabama Research Center — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.